NEW YORK (GenomeWeb) – 23andMe has raised $250 million in funding, the consumer genomics firm announced today.

23andMe said it plans to use the money to grow its customer base, expand its therapeutics group, and invest in its genetic research platform. With this latest funding, 23andMe has raised $491 million from a range of investors, including technology and health science companies, angel investors, and venture capital firms.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.